PULMONARY FIBROSIS

✓ Medically ReviewedDISEASEID: MDBT0180🚨 TRIAGE: URGENTICD-10: J84.1

📖

Definition

CLINICAL DEFINITION

Pulmonary fibrosis is a pathological process characterised by the progressive scarring and thickening of the interstitium of the lungs, leading to irreversible architectural distortion, impaired gas exchange, and a restrictive ventilatory defect. It represents the end-stage of various interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), connective tissue disease-associated ILD, and chronic hypersensitivity pneumonitis.

IN PLAIN ENGLISH

Pulmonary fibrosis is a condition where the tissue deep in your lungs becomes scarred, thickened, and stiff over time. This scarring makes it difficult for your lungs to expand and for oxygen to pass into your bloodstream, leading to progressive shortness of breath.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

Pulmonary fibrosis is NOT simply chronic bronchitis or emphysema (COPD), which primarily affect the airways and alveolar spaces rather than the interstitium. It is also NOT an acute infectious pneumonia, although acute exacerbations can occur on top of the chronic fibrotic process.

🔤

Word Breakdown

fibr-

=fibre or fibrous tissue (from Latin 'fibra'); 'pulmonary' derives from Latin 'pulmo' meaning lung

-osis

=abnormal condition or disease process (from Greek '-osis')

Literal Meaning: An abnormal condition of fibrous tissue formation in the lungs

🏷️

Abbreviations

PF=Pulmonary Fibrosis — general term for scarring of lung tissue

IPF=Idiopathic Pulmonary Fibrosis — the most common and severe form of idiopathic interstitial pneumonia

UIP=Usual Interstitial Pneumonia — the histopathological and radiological pattern most commonly associated with IPF

FVC=Forced Vital Capacity — key spirometric measure used to monitor disease progression

DLCO=Diffusing Capacity of the Lungs for Carbon Monoxide — measures gas exchange impairment

🔄

Synonyms & Variants

Interstitial Lung Disease with Fibrosis›Fibrosing Interstitial Pneumonia›Cryptogenic Fibrosing Alveolitis›

🎯

Category-Specific Context

As a disease, pulmonary fibrosis represents the common final pathway of a heterogeneous group of interstitial lung diseases (ILDs). It is classified based on aetiology (idiopathic, autoimmune, environmental, drug-induced) and radiological/histopathological patterns (e.g., usual interstitial pneumonia [UIP], non-specific interstitial pneumonia [NSIP]).

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Respiratory Medicine Outpatient ClinicInterstitial Lung Disease Multidisciplinary MeetingGeneral Medicine WardRheumatology ClinicPalliative Care Unit

USAGE & DOCUMENTATION NOTES

In clinical documentation, 'pulmonary fibrosis' is often used as a broad descriptive term, but specialists prefer specifying the aetiology and radiological pattern (e.g., 'IPF with a UIP pattern on HRCT'). Lung function trends are typically documented as percentage change in FVC and DLCO over 6–12 months. The phrase 'honeycombing' is frequently used in radiology reports to denote advanced, irreversible fibrotic destruction.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

Pulmonary fibrosis arises from aberrant wound healing in response to recurrent or chronic micro-injuries to the alveolar epithelium. In susceptible individuals, particularly with age-related genetic predispositions, the normal regenerative capacity of alveolar type II pneumocytes is exhausted. This leads to the recruitment and activation of fibroblasts, which differentiate into myofibroblasts and form fibroblastic foci. These myofibroblasts deposit excessive extracellular matrix proteins, primarily collagen and fibronectin, into the interstitial space. The progressive accumulation of this stiff, fibrotic tissue destroys the normal alveolar-capillary architecture, thickening the diffusion barrier, reducing lung compliance, and causing a restrictive ventilatory defect with impaired gas exchange.

PRIMARY CAUSES

Idiopathic

Unknown environmental or endogenous triggers interact with genetic susceptibility (e.g., MUC5B promoter variant, telomerase mutations) causing aberrant epithelial repair and progressive fibrogenesis, manifesting as Idiopathic Pulmonary Fibrosis (IPF).

Connective Tissue Diseases (CTD)

Systemic autoimmune inflammation (e.g., Rheumatoid Arthritis, Systemic Sclerosis) targets the pulmonary interstitium, leading to chronic inflammatory infiltration and subsequent fibrotic remodelling.

Environmental and Occupational Exposures

Chronic inhalation of inorganic dusts (asbestos, silica) or organic antigens (hypersensitivity pneumonitis) triggers persistent alveolitis, macrophage activation, and pro-fibrotic cytokine release.

Drug and Radiation Toxicity

Direct cytotoxic injury to alveolar epithelial cells by agents such as amiodarone, bleomycin, or thoracic radiotherapy initiates an inflammatory cascade that culminates in fibrotic scarring.

💊

Drug-Induced Causes

💊 Antiarrhythmics (Amiodarone) ↗

Mechanism: Direct cytotoxicity and phospholipidosis in alveolar macrophages and type II pneumocytes trigger chronic interstitial inflammation.

→ Discontinue amiodarone immediately if suspected; initiate systemic corticosteroids for symptomatic pneumonitis/fibrosis, though established fibrosis is irreversible.

💊 Chemotherapeutic agents (Bleomycin, Busulfan, Cyclophosphamide) ↗

Mechanism: Generation of reactive oxygen species and direct DNA damage to pulmonary epithelium, leading to fibroblast proliferation.

→ Stop the offending agent; monitor pulmonary function closely; corticosteroids may be used for acute pneumonitis, but prevention via dose-limiting is key.

💊 Nitrofurantoin (chronic use) ↗

Mechanism: Chronic hypersensitivity reaction or direct toxic effect on the pulmonary interstitium causing progressive fibrosis.

→ Discontinue nitrofurantoin; corticosteroids may accelerate recovery in the inflammatory phase.

💊 Biologic agents (Immune checkpoint inhibitors) ↗

Mechanism: Immune-related adverse events causing checkpoint inhibitor pneumonitis, which can progress to fibrosis if not recognised and treated early.

→ Hold immunotherapy; administer high-dose systemic corticosteroids (e.g., prednisolone 1-2 mg/kg) and taper slowly; consider infliximab or mycophenolate for steroid-refractory cases.

🌍

Epidemiology

Prevalence:The global prevalence of interstitial lung diseases (ILDs) leading to pulmonary fibrosis is estimated at 14 to 42 per 100,000 population. The prevalence of Idiopathic Pulmonary Fibrosis (IPF) specifically is estimated between 13 and 63 per 100,000 individuals in Europe and North America, with incidence rising with age.

Age Group:Primarily affects older adults. IPF is typically diagnosed in individuals aged 60–75 years. Connective tissue disease-associated and hypersensitivity pneumonitis-related fibrosis can present in middle-aged adults (40–60 years).

Sex Predilection:Male

Geographic Distribution:Higher prevalence and incidence rates of IPF are reported in North America and Europe compared to Asia and South America, though this may reflect differences in diagnostic practices, awareness, and access to HRCT.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

Rapidly worsening dyspnoea with new ground-glass opacities on imaging in a known fibrosis patient raises high suspicion for an acute exacerbation of IPF or opportunistic infection, requiring urgent hospitalisation, broad-spectrum antimicrobials, and consideration of high-dose corticosteroids.
Unexplained pulmonary fibrosis in a patient with joint pain, Raynaud's phenomenon, or skin thickening strongly suggests an underlying connective tissue disease, necessitating comprehensive autoimmune serology and rheumatology evaluation.

URGENT EVALUATION TRIGGERS

Acute worsening of dyspnoea over days to weeks, suggesting acute exacerbation or superimposed infection.
New onset resting hypoxaemia (SpO2 < 88%) or significant exertional desaturation.
Development of signs of right heart failure (e.g., new peripheral oedema, elevated JVP, loud P2), indicating progressive pulmonary hypertension.

Contraindications & Precautions

CONTRAINDICATIONS

Systemic corticosteroids as monotherapy for IPF — contraindicated due to increased mortality and adverse effects
as demonstrated in the PANTHER-IPF trial.
Live vaccines in patients on heavy immunosuppression for CTD-associated fibrosis — risk of disseminated infection.

SPECIAL PRECAUTIONS

Oxygen therapy — titrate carefully in patients with concomitant COPD or chronic hypercapnia to avoid suppressing hypoxic respiratory drive.
Surgical lung biopsy — carries high morbidity and mortality in patients with advanced fibrotic disease or severe pulmonary hypertension; transbronchial cryobiopsy or HRCT diagnosis is preferred when feasible.
Antifibrotic therapy — monitor liver function tests regularly (e.g.
monthly for the first 3 months
then every 3 months) as nintedanib and pirfenidone can cause hepatotoxicity.

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Progressive respiratory failure — irreversible loss of gas exchange capacity leading to chronic hypoxaemia and eventual hypercapnia.
Pulmonary hypertension (Group 3) — chronic hypoxia and vascular bed destruction cause elevated pulmonary arterial pressures and right heart strain.
Acute exacerbation of IPF — sudden
clinically significant respiratory deterioration with new bilateral ground-glass opacities or consolidation
carrying a very high mortality rate.
Lung cancer — patients with IPF have a significantly increased risk of developing primary bronchogenic carcinoma
independent of smoking history.
Cor pulmonale — right ventricular hypertrophy and failure secondary to chronic pulmonary hypertension.

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

Cystic Fibrosis

Both contain 'fibrosis' and affect the lungs, but Cystic Fibrosis is a genetic disorder of exocrine glands causing thick mucus and bronchiectasis, whereas Pulmonary Fibrosis is an interstitial scarring disease.

Pulmonary Embolism

Both present with acute or progressive dyspnoea and hypoxia, but PE is a vascular occlusive disease, not an interstitial fibrotic process.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Chronic Obstructive Pulmonary Disease (COPD)

Key Distinguishing Feature: COPD presents with an obstructive pattern on spirometry (FEV1/FVC < 0.70) and hyperinflation, whereas pulmonary fibrosis causes a restrictive pattern with reduced FVC and TLC.

Chronic Hypersensitivity Pneumonitis

Key Distinguishing Feature: Requires identification of a specific environmental antigen exposure; may show upper/mid-zone predominance and airway-centred fibrosis on HRCT, unlike the basal/subpleural predominance of UIP/IPF.

Heart Failure

Key Distinguishing Feature: Presents with dyspnoea and crackles, but features cardiomegaly, pleural effusions, and elevated BNP, rather than interstitial reticulation and honeycombing on HRCT.

💎

Clinical Pearls

💎

The presence of a Usual Interstitial Pneumonia (UIP) pattern on HRCT in the appropriate clinical context is sufficient to diagnose Idiopathic Pulmonary Fibrosis (IPF) without the need for a surgical lung biopsy, sparing the patient procedural risks.

💎

Antifibrotic therapies (pirfenidone and nintedanib) do not reverse existing fibrosis or cure the disease; their primary goal is to slow the rate of decline in Forced Vital Capacity (FVC). Early initiation is associated with better long-term preservation of lung function.

💎

A multidisciplinary discussion (MDD) involving respiratory physicians, radiologists, and pathologists significantly increases diagnostic accuracy and inter-observer agreement for complex interstitial lung diseases compared to individual assessment.

💎

Always review the patient's medication history thoroughly, as drug-induced interstitial lung disease can mimic idiopathic forms, and early withdrawal of the offending agent may halt progression before irreversible fibrosis occurs.

📝

Example Usage & SOAP

CLINICAL SENTENCE

"The patient's HRCT chest demonstrated bilateral, basal-predominant subpleural reticulation and honeycombing consistent with a UIP pattern, supporting a diagnosis of idiopathic pulmonary fibrosis."

IN A SOAP NOTE

S: 68-year-old male with a 12-month history of progressive exertional dyspnoea and a chronic dry cough. Reports no chest pain or haemoptysis. Former smoker (20 pack-years, quit 15 years ago). O: RR 18, SpO2 94% on room air at rest, desaturates to 86% on exertion. Fine end-inspiratory 'Velcro' crackles heard bilaterally at the lung bases. Digital clubbing present. FVC 68% predicted, DLCO 45% predicted. A: Idiopathic Pulmonary Fibrosis (IPF) with a UIP pattern on HRCT. No evidence of connective tissue disease on serology. P: 1. Initiate antifibrotic therapy with nintedanib after baseline LFTs. 2. Refer to pulmonary rehabilitation. 3. Prescribe ambulatory oxygen therapy for exertional desaturation. 4. Vaccinate against influenza and pneumococcus. 5. Discuss advance care planning and lung transplant referral criteria.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for progressive dyspnoea with interstitial changes on imaging: (1) Idiopathic Pulmonary Fibrosis — suggested by age >60, basal/subpleural honeycombing, and absence of systemic symptoms. (2) Connective Tissue Disease-ILD — considered if patient has Raynaud's, arthritis, or positive autoantibodies (e.g., anti-Scl-70, anti-Jo-1). (3) Chronic Hypersensitivity Pneumonitis — suspected if there is a history of avian or mould exposure, often with upper/mid-zone predominance and mosaic attenuation. (4) Drug-induced ILD — requires careful medication review (e.g., amiodarone, nitrofurantoin, methotrexate).

📊

Classifications & Scoring

STAGING SCALE

GAP Index (Gender, Age, Physiology)

A staging system for Idiopathic Pulmonary Fibrosis that predicts mortality. Uses Gender (male=1), Age (points for >60, >65), and Physiology (FVC % predicted and DLCO % predicted). Stages I, II, and III correlate with 1-year and 3-year mortality risks.

Scale Reference ↗

📈

Prognosis

SHORT-TERM OUTCOME

In stable disease, short-term prognosis is generally favourable with appropriate monitoring. However, an acute exacerbation of IPF carries a short-term in-hospital mortality rate exceeding 50%.

LONG-TERM PROGNOSIS

The median survival for untreated IPF is historically 2 to 5 years from diagnosis, though antifibrotic therapies (nintedanib, pirfenidone) slow the rate of FVC decline and may improve long-term survival. Prognosis for CTD-associated fibrosis is highly variable and depends on the underlying autoimmune disease activity and response to immunosuppression.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

J84.1

LITERATURE CITATIONS & GUIDELINES

[1]Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68.

[2]Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018;378(19):1811-1823.

[3]Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-740.

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.